Agenus Dirección
Dirección controles de criterios 2/4
Agenus' El consejero delegado es Garo Armen , nombrado en Jan 1994, tiene un mandato de 30.08 años. la remuneración anual total es $5.63M , compuesta por 12.2% salario y 87.8% primas, incluidas acciones y opciones de la empresa. posee directamente 0.48% de las acciones de la empresa, por valor de $1.21M . La antigüedad media del equipo directivo y del consejo de administración es de 2.1 años y 5.3 años respectivamente.
Información clave
Garo Armen
Chief Executive Officer (CEO)
US$5.9m
Compensación total
| Porcentaje del salario del CEO | 12.1% |
| Permanencia del CEO | 30.3yrs |
| Participación del CEO | 0.6% |
| Permanencia media de la dirección | 2.3yrs |
| Promedio de permanencia en la Junta Directiva | 5.4yrs |
Actualizaciones recientes de la dirección
Recent updates
Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet
Mar 29
Agenus: 2024 May Finally Be The Year For A Major Turnaround
Jan 18Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet
Dec 22News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts
Nov 09A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)
Oct 04Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts
May 10VBI Vaccines, Agenus to examine VBI-1901 + balstilimab combo for glioblastoma
Oct 12Agenus New Trials Set It Up For The Long Haul
Sep 27Agenus: It's Always Tomorrow
Sep 16Agenus GAAP EPS of -$0.17, revenue of $20.93M
Aug 09Agenus: Successfully Pulled Itself Away From Disaster
Jul 04Agenus: Not Quite Enough
Apr 19Auditors Have Doubts About Agenus (NASDAQ:AGEN)
Mar 06Agenus: Making Another Effort With The FDA
Jan 25Agenus Inc.'s Imminent 1181/Bal Data Release And MiNK IPO Should Lead To Enormous Valuation Gains
Aug 25Agenus Multiple Value-Adding Events Ahead
Aug 18Party Time: Brokers Just Made Major Increases To Their Agenus Inc. (NASDAQ:AGEN) Earnings Forecasts
Aug 11FDA accepts Agenus' balstilimab BLA under "priority review" status
Jun 17Agenus/Bristol-Myers Squibb Deal Makes For A Strong Buy
May 26Agenus shares fall after Q1 topline miss
May 06Is Agenus Inc. (NASDAQ:AGEN) Popular Amongst Institutions?
Feb 15Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$6m | US$710k | -US$246m |
| Sep 30 2023 | n/a | n/a | -US$271m |
| Jun 30 2023 | n/a | n/a | -US$263m |
| Mar 31 2023 | n/a | n/a | -US$240m |
| Dec 31 2022 | US$6m | US$689k | -US$220m |
| Sep 30 2022 | n/a | n/a | -US$215m |
| Jun 30 2022 | n/a | n/a | US$18m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | US$10m | US$655k | -US$24m |
| Sep 30 2021 | n/a | n/a | US$4m |
| Jun 30 2021 | n/a | n/a | -US$226m |
| Mar 31 2021 | n/a | n/a | -US$190m |
| Dec 31 2020 | US$6m | US$677k | -US$181m |
| Sep 30 2020 | n/a | n/a | -US$174m |
| Jun 30 2020 | n/a | n/a | -US$168m |
| Mar 31 2020 | n/a | n/a | -US$171m |
| Dec 31 2019 | US$10m | US$634k | -US$108m |
| Sep 30 2019 | n/a | n/a | -US$126m |
| Jun 30 2019 | n/a | n/a | -US$113m |
| Mar 31 2019 | n/a | n/a | -US$87m |
| Dec 31 2018 | US$3m | US$610k | -US$160m |
| Sep 30 2018 | n/a | n/a | -US$147m |
| Jun 30 2018 | n/a | n/a | -US$151m |
| Mar 31 2018 | n/a | n/a | -US$158m |
| Dec 31 2017 | US$4m | US$593k | -US$121m |
Compensación vs. Mercado: Garo($USD5.63M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.53M).
Compensación vs. Ingresos: Garoha aumentado mientras la empresa no es rentable.
CEO
Garo Armen (70 yo)
30.3yrs
Permanencia
US$5,856,319
Compensación
Dr. Garo H. Armen, Ph.D. founded Agenus Inc. in 1994 and has been Chief Executive Officer since 1994. He serves as an Executive Chairman at MiNK Therapeutics, Inc. Dr. Armen serves as an Executive Chairman...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 30.3yrs | US$5.86m | 0.58% $ 649.0k | |
| VP of Finance | 17.5yrs | US$712.75k | 0.037% $ 40.9k | |
| Chief Medical Officer | 3.3yrs | US$1.44m | 0.065% $ 72.3k | |
| Chief Information Officer | 2.3yrs | sin datos | sin datos | |
| Head of Investor Relations | no data | sin datos | sin datos | |
| Chief People Officer | 2.3yrs | sin datos | sin datos | |
| Scientific Director & Head of Drug Discovery | no data | sin datos | sin datos | |
| Chief Manufacturing Officer | no data | sin datos | sin datos | |
| Chief Quality Officer | 2.3yrs | sin datos | sin datos | |
| Member of Advisory Board & Chief Strategic Advisor | less than a year | sin datos | sin datos | |
| Chief Commercial Officer | less than a year | sin datos | sin datos | |
| Chief Medical Affairs Officer | less than a year | sin datos | sin datos |
2.3yrs
Permanencia media
62yo
Promedio de edad
Equipo directivo experimentado: AGENEl equipo directivo de la empresa se considera experimentado (2 años de antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 25.3yrs | US$5.86m | 0.58% $ 649.0k | |
| Member of Advisory Board & Chief Strategic Advisor | 1.3yrs | sin datos | sin datos | |
| Member of Advisory Board | 1.3yrs | US$1.04m | sin datos | |
| Independent Director | 7.9yrs | US$366.39k | 0.030% $ 32.9k | |
| Independent Lead Director | 17.3yrs | US$385.50k | 0.013% $ 14.7k | |
| Member of Advisory Board | 1.3yrs | sin datos | sin datos | |
| Independent Director | 17.1yrs | US$888.14k | 0.022% $ 24.4k | |
| Independent Director | 3.5yrs | US$242.00k | 0.028% $ 31.5k | |
| Independent Director | 5.4yrs | US$242.00k | 0.016% $ 17.6k |
5.4yrs
Permanencia media
67yo
Promedio de edad
Junta con experiencia: La junta directiva de AGEN se considera experimentada (5.1 años de antigüedad promedio).